Platelet-derived Microvesicles in Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome

Summary

Thrombotic thrombocytopenic purpura (TTP) and the related hemolytic uremic syndrome (HUS) are disorders characterized by thrombocytopenia, microangiopathic hemolytic anemia, a variable degree of impairment of renal function and fluctuating neurological symptoms, which are thought to be due to platelet activation and subsequent formation of thrombi in the microcirculation. Since platelet activation is accompanied by the generation of microvesicles (PMPs), we determined their presence in patients with TTP and HUS by flow cytometry. The analysis was performed in whole blood, using FITC-conjugated monoclonal antibodies (CD 42b and/or CD 61a). PMPs were discriminated from platelets on the basis of size and fluorescence profiles. Their levels in 21 normal controls ranged between 2.4% and 9.4% (mean ± SD: 5.2 ± 1.99%). No correlations were found with platelet number. PMPs were then evaluted in 13 patients with TTP and 2 cases of HUS. In all patients they were found higher than in controls, ranging from 11.0 to 91.1% (45.0 ± 26.0%; p = 0.0001 vs controls). PMPs were serially measured in patients with TTP: at diagnosis a correlation between PMPs and platelet number was found (R^2 = 0.669) and the time-course showed that the improvement of both microangiopathy and clinical manifestations of cerebral and renal involvement was accompanied by a progressive normalization of PMP levels and platelet count.

PMP levels were measured also in patients suffering from other forms of thrombocytopenia: they were 17 patients with idiopathic thrombocytopenic purpura and 10 patients with acute leukemias and severe thrombocytopenia during the aplastic phase following chemotherapy. PMP ranges were: 2.0−79.6% (21.6 ± 20.8%; p = 0.001 vs controls) and 4.6−12.5% (8.8 ± 2.4%; p = 0.0001 vs controls), respectively. No correlations were found between platelet number and the absolute number of PMPs in these 2 groups of patients.

These findings show that increased levels of PMPs may be found in peripheral thrombocytopenias and suggest that their presence may be clinically relevant, particularly in the microangiopathic forms.

• References

• 1 Byrnes JJ, Moake JL. Thrombotic thrombocytopenic purpura and haemo-lytic-uraemic syndrome: evolving concepts of pathogenesis and therapy. Clin Haematol 1986; 15: 4135-4142
• 2 Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32: 292-308
• 3 Berkowitz LR, Dalldorf FG, Blatt PM. Thrombotic thrombocytopenic purpura. A pathology review. JAMA 1979; 241: 1709-1710
• 4 Karmali MA, Stelle BT, Petrie M, Lim C. Sporadic cases of hemolytic-uremic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; i: 619-620
• 5 Kovacs MS, Roddy J, Gregoire S, Cameron W, Eidus L, Drovin J. Thrombotic thrombocytopenic purpura following hemorrhagic colitis due to Escherichia coli 0157:H7. Am J Med 1990; 88: 177-179
• 6 Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Deykin D. Unusually large plasma factor VIII: von Willebrand factor in thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435
• 7 Kelton JG, Warkentin TE, Hayward CPM, Murphy WG, Moore JC. Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microvesicles. Blood 1992; 80: 2246-2251
• 8 Falanga A, Consonni R, Ruggenenti P, Barbui T. A cathepsin-like cysteine proteinase proaggregating activity in thrombotic thrombocytopenic purpura. Br J Haematol 1991; 79: 474-480
• 9 Consonni R, Falanga A, Barbui T. Further characterization of platelet-aggregating cysteine proteinase activity in thrombotic thrombocytopenic purpura. Br J Haematol 1994; 87: 32124
• 10 Meister RJ, Sacher RA, Phillips T. Immune complexes in thrombotic thrombocytopenic purpura. Ann Intern Med 1979; 90: 717
• 11 Morrison J, McMillan R. Elevated platelet-associated IgG in thrombotic thrombocytopenic purpura. JAMA 1977; 238: 1944
• 12 Leung DYM, Moake JL, Havens PL, Kim M, Pober JS. Lytic antiendothe-lial cell antibodies in hemolytic-uremic syndrome. Lancet 1988; ii: 183-186
• 13 Schroit AJ, Zwaal RFA. Transbilayer movement of phospholipids in red cells and platelet membranes. Biochim Biophys Acta 1991; 1071: 313-329
• 14 Wolf W. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 26988
• 15 George JN, Pickett EB, Heinz R. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood 1986; 68: 307-309
• 16 Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-138
• 17 George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-348
• 18 Holme PA, Solum NO, Brosstad F, Roger M, Abdelnoor M. Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and western blotting. Thromb Haemost 1994; 72: 666-671
• 19 Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenia. J Lab Clin Med 1992; 119: 334-345
• 20 Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard J-AI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-3699
• 21 Finanzzi G, Bellavita P, Falanga A, Viero P, Barbui T. Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Am J Hematol 1992; 41: 165-169
• 22 Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77: 31-33
• 23 Galbusera M, Ruggenenti P, Noris M, Burnouf-Radosevich M, Benigni A, Mannucci PM, Remuzzi G. α 1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. Lancet 1995; 345: 224-225
• 24 Zwaal RFA, Comfurius P, Bevers EM. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1992; 1180: 1-8
• 25 Owens MR, Holme S, Cardinali S. Platelet micro vesicles adhere to subendothelium and promote adhesion of platelets. Thromb Res 1992; 66: 24758
• 26 Anderson JP. Insights into heparin-induced thrombocytopenia. Br J Haematol 1992; 80: 504-508
• 27 Boshkow LK, Warkentin TE, Hayward CPM, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-328
• 28 Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. N Engl J Med 1991; 325: 398-403
• 29 Hoffman M, Monroe DM, Roberts HR. Platelet activation with thrombotic thrombocytopenic purpura. Am J Hematol 1993; 42: 182-185
• 30 Hourdille P, Heilmann E, Combrie R, Winckler J, Clemetson KJ, Nurden AT. Thrombin induces a rapid redistribution of glycoprotein Ib-IX complex within the membrane systems of activated platelets. Blood 1990; 76: 1503-1513
• 31 Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK. Comparison of platelet membrane markers for the detection of platelet activation in vitro and during platelet storage and cardiopulmonary bypass surgery. J Lab Clin Med 1993; 121: 579-587